Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia

COVID-19 Pneumonia Clinical Trial

Official title:

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of EG-009A Compared to Dexamethasone in Patients With Moderate/Severe (Non-intubated, Non-mechanical Ventilation) COVID-19 Pneumonia

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04561180
• Other study ID #: HPC-EG-009A-2.1
• Status: Withdrawn
• Phase: Phase 2
• Start date: March 4, 2022
• Est. completion date: May 1, 2023

Study information

• Verified date: July 2023
• Source: Evergreen Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 1, 2023
• Est. primary completion date: May 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under International Conference on Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (age =18), or willing and able to provide assent (age =12 to <18, where locally and nationally approved) prior to performing study procedures

2. Patient is aged at least 18 years, enrollment of patients < 65 years old will be limited to 20% of the total with the first 50% of enrollment conducted solely among those patients = 55 years old.

3. Patient has SARS-CoV-2 pneumonia from COVID-19 infection of moderate to serious severity (WHO Ordinal Scale for Clinical Improvement score of 4 or 5)

4. Patient has COVID-19 symptoms = 10 days and at least 1 of the following:

• Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.)
• O2 saturation (SpO2) = 94% on room air
• Requiring supplemental O2 (patients on HFNO = 20 L/min with FiO2 < 0.5 are allowed), but not requiring mechanical ventilation. Note: Patients admitted with immediate need for mechanical ventilation are of a severity too critical for inclusion into this protocol. Patients who are already in the hospital and have been removed from mechanical ventilation are not eligible.

Exclusion Criteria:

1. Patient has SARS-CoV-2 infection of severity = 6 on COVID-19 WHO Ordinal Scale for Clinical Improvement or for those subjects who have a WHO Ordinal Scale for Clinical Improvement score of 5, nasal intermittent positive pressure ventilation (NIPPV) or requiring HFNO > 20 L/min with FiO2 = 0.5 will be exclusionary.

2. Patient is currently receiving extracorporeal membrane oxygenation, nitric oxide therapy, or high-frequency oscillatory ventilation

3. Patient is unlikely to survive for > 24 hours from randomization, in the opinion of the investigator

4. Patient has a history of chronic oxygen use or any pre-existing respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization

5. Patient has a history of venous thromboembolism, DVT, or pulmonary embolus

6. Has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug's PK, PD, or biological activity (if known), whichever is longer, prior to the first dose of study drug in this study or is currently participating in another clinical study.

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Pneumonia
• Pneumonia

Intervention

Drug:
• EG-009A
Administered as an Intramuscular injection
• EG-009A Placebo
Administered as an Intramuscular injection
• Standard of Care
Standard of Care Treatment for COVID-19 Infection
• Dexamethasone
The comparator, Administered as an Intravenous infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Evergreen Therapeutics, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of patients alive and without respiratory failure	Patients will be assessed for COVID-19 Ordinal Scale for Clinical Improvement scores and respiratory status throughout the study	First dose date to 28 days treatment dosing period